Pacific Shuanglin Bio-pharmacy Hits Day Low at CNY 11.75 Amid Price Pressure

Pacific Shuanglin Bio-pharmacy Co., Ltd. experienced a notable decline today, with the stock dropping by 3.5% on June 9, 2026. The stock reached an intraday low of CNY 11.75, reflecting ongoing challenges within the company. Over the past week, the stock has decreased by 4.44%, while its performance over the last month shows a modest increase of 1.11%. However, the longer-term outlook remains concerning, with a significant year-to-date decline of 13.51% and a staggering 30.19% drop over the past year. The company's financial metrics indicate a decline in net sales by 8.47%, contributing to negative results reported for six consecutive quarters. Operating cash flow has also reached a low of CNY -201.95 million, and the return on capital employed stands at just 4.38%. Despite being classified as a large-cap company with a market capitalization of CNY 11,543 million, Pacific Shuanglin Bio-pharmacy's performance has consistently lagged behind the China Shanghai Composite index across various time frames, including a 40.2% decline over the past three years.